History
TOYO JOZO
ASAHI KASEI
-
1920
Toyo Jozo Co., Ltd. established, successor to sake brewery Wakita Shuzo
-
1931
Nobeoka Ammonia Fiber Co., Ltd. established
-
1946
Corporate name changed to Asahi Chemical Industry Co., Ltd.
-
1947
Penicillin launched
-
1955
Antibiotic agent Leucomycin™ (kitasamycin) launched
-
1958
Capital tie-up with Toyo Jozo Co., Ltd.
-
-
1969
Synthesized penicillin launched
-
1969
Inosine, a nucleoside, launched
-
-
1970
Bacitracin, an antibiotic feed additive, launched
-
-
1974
Enzymes developed for triglyceride measurement
-
1974
Colistin, an antibiotic feed additive, launched
-
-
1976
Pharmaceutical product operations begin
-
1978
Anticancer agent Sunfural™ (tegafur) launched
-
-
1981
Synthetic calcitonin derivative Elcitonin™ (elcatonin) launched for the treatment of osteoporosis
-
1981
Ubidecarenone (coenzyme Q10) launched
-
-
-
1983
Anti-allergy agent Zesulan™ (mequitazine) launched
-
1983
Anticancer agent Sunrabin™ (enocitabine) launched
-
-
1984
Immunosuppressant Bredinin™ (mizoribine) launched for renal transplantation rejection
-
1986
Antibiotic agent Ricamycin™ (rokitamycin) launched
-
1988
Antibiotic agent Exacin™ (isepamicin) launched
-
1989
Acquisition of International Contact Lenses Co., Ltd.
-
1991
Plasvata™ (tisokinase) launched for the treatment of acute myocardial infarction
-
1992
Toyo Jozo Co., Ltd. merges with Asahi Chemical Industry Co., Ltd.
-
1993
Elcitonin™ (elcatonin) Injection 20S launched for the treatment of osteoporosis
-
1995
Rho-kinase inhibitor Eril™ (fasudil) launched
-
1999
Flivas™ (naftopidil) launched for the treatment of dysuria accompanying benign prostatic hyperplasia
-
2000
Toledomin™ (milnacipran hydrochloride) launched for the treatment of depression
-
2001
Corporate name changed to Asahi Kasei Corporation
-
2003
Asahi Kasei Pharma Corporation begins operation following the transformation of Asahi Kasei Corporation to a holding company configuration
-
2004
LUCICA™ GA-L assay kit launched for the measurement of glycated albumin (GA)
-
2008
Recomodulin™ (thrombomodulin alfa) launched for the treatment of disseminated intravascular coagulation (DIC)
-
2008
Famvir™ (famciclovir) launched for the treatment of herpes zoster
-
2011
Teribone™ (teriparatide acetate) launched for the treatment of osteoporosis with high risk of fracture
Asahi Kasei Pharma America Corp. established
-
2011
Asahi Kasei Pharma America Corp. established
-
2013
Ribotest™ Mycoplasma assay kit launched for the detection of Mycoplasma pneumoniae antigen
-
2015
Asahi Kasei Pharma (Beijing) Co., Ltd. established
-
2015
Xiaflex® (collagenase clostridium histolyticum) launched for the treatment of Dupuytren's contracture
-
2016
Reclast™ (zoledronic acid) launched for the treatment of osteoporosis
-
2018
Kevzara® (sarilumab) launched for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional treatments
-
2019
Ribotest™ Legionella assay kit launched for the detection antigen and urinary Legionella pneumophila L7/L12 antigen
-
2021
Ribotest™ Pertussis assay kit launched for the detection of Bordetella pertussis antigen
-
2021
Plaquenil®（hydroxychloroquine sulfate）launched for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE)
-
2023
Cresemba™ (isavuconazonium sulfate) launched for an azole antifungal drug for fungal infections, such as Aspergillosis, Mucormycosis, and Cryptococcosis
-
2023
Doptelet® (avatrombopag maleate) launched for a thrombopoietin receptor agonist, which is an agent for improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure
-
2023
Empaveli® (pegcetacoplan) launched for a PEGylated peptide1 inhibiting the function of complement protein C3 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)
* Notes: Toledomin™ is a registered trademark of Pierre Fabre Medicament SA. Famvir™ is a registered trademark of Novartis Pharma AG. Xiaflex® is a registered trademark of an affiliate of Endo International plc.